Evidence map›Paper›PMID 40425059›Full record

ArticleInternational journal of pharmaceutics2025

A nanoparticle platform for the co-delivery of multiple antigen epitope peptides and STING agonist to lymph nodes for cancer immunotherapy.

Xiyu Ke, Brady A Campbell, Xiaoya Lu, Betul Celiker, Lei Zheng, May Tun Saung, Hai-Quan Mao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiyu KeInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA; Department of Materials Science and Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, USA.
Brady A CampbellThe Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xiaoya LuInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA; Department of Materials Science and Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, USA.
Betul CelikerThe Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lei ZhengThe Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Pancreatic Cancer Precision Medicine Center of Excellence, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: lzheng6@jhmi.edu.
May Tun SaungThe Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Pancreatic Cancer Precision Medicine Center of Excellence, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: msaung1@jhmi.edu.
Hai-Quan MaoInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA; Department of Materials Science and Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: hmao@jhu.edu.

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
Clinical and Laboratory Research Training for Surgical OncologistsT32CA126607 · NCI · JOHNS HOPKINS UNIVERSITY · PI CAMERON, ANDREW M. · 2008 to 2024
$6.0M
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical TrialR01CA197296 · NCI · JOHNS HOPKINS UNIVERSITY · PI William Reece Burns, Eric Christenson · 2015 to 2026
$5.7M
Interrogate the interaction between tumor cells and nerves in the tumor microenvironment of pancreatic cancerR01CA169702 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ZHENG, LEI · 2013 to 2023
$3.6M
Kinetic Assembly of Polymer-mRNA Nanoparticles Targets Circulating Monocytes to Enhance Cancer ImmunotherapyR01CA281143 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jordan Green, Hai-Quan Mao · 2023 to 2026
$2.3M
NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA169702NCI NIH HHS R01 CA197296NCI NIH HHS R01 CA281143NCI NIH HHS T32 CA126607
6 · The paper itself

Abstract

Nanoparticles loaded with cancer epitope peptides have shown great potential for cancer immunotherapy. However, preparing small-sized nanoparticles with a narrow size distribution for the co-delivery of multiple antigen peptides has been a challenge. The lack of scalable and reproducible nanoparticle preparation methods has also hindered the widespread application of nanoparticles in cancer immunotherapy. In this study, we developed lymph node-targeted nanoparticles for the co-delivery of a group of sixteen pancreatic cancer antigen peptides and a STING agonist as an adjuvant using the flash nanocomplexation (FNC) method. The nanoparticles generated by FNC had a smaller particle size and a narrower size distribution compared to the nanoparticles prepared by bulk mixing. The FNC-generated nanoparticles enhanced human monocyte activation, demonstrated lymph node-targeting effect, and activated dendritic cells in vivo, all without any observable toxicity. Additionally, in vivo studies demonstrated the strong anti-tumor efficacy of these nanoparticles in an orthotopic pancreatic cancer mouse model. This nanoparticle platform enables the effective co-delivery of multiple antigen epitope peptides and an adjuvant to the lymph nodes. Furthermore, the scalability and reproducibility of the FNC method could facilitate the rapid clinical translation of this nanoparticle platform.

Indexed as

Antigens, NeoplasmEpitopesLymph NodesMembrane ProteinsNanoparticlesPancreatic NeoplasmsPeptidesAdjuvants, ImmunologicAnimalsCell Line, TumorDendritic CellsFemaleHumansImmunotherapyMiceMice, Inbred C57BLAdjuvants, ImmunologicAntigens, NeoplasmEpitopesMembrane ProteinsPeptidesSTING1 protein, humanSTING ProteinCancer immunotherapyCancer vaccineNanoparticle formulationPancreatic cancerSTING agonist

Identifiers

PMID40425059
PMCPMC12167128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.